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tive analysis aims to explore how PRO were used in the French affiliate of 
Roche. Methods: A total of 89 local studies performed between 2003 and 2013 
were evaluated to determine how PROs were collected and evaluated. Results: 
Forty (45%) out of 89 studies were clinical trials, 44 (49%) were non-interventional 
studies (NIS) and 5 were expanded access program studies. A total of 33 (37%) 
studies used at least one PRO; 13 (39%) were clinical trials and 20 (61%) were NIS. 
There were no PRO in the field of transplantation, 21% of the studies in oncology 
used PRO, 47% in virology, 60% in anemia and 72% in rheumatology. More than 3600 
sites participated in the 33 studies using PRO: 17424 patients were included, 14237 
patients (82%) answered at least one PRO and 12314 (86%) of the questionnaires 
received were considered to be analyzable for statistical analysis (non analyzable 
PROs were usually due to missing data). The median number of questionnaires 
per study was 2, (range 1-6). While most studies in virology and anemia used 1 or 
2 questionnaires per study, rheumatology studies used at least 3 questionnaires 
per study. The median study duration was 12 months, (range 1-60). While 84% of 
PRO were collected at inclusion in the study, 73% of PROs were received after the 
6 month visit, 65% at the 12 month visit and less than 50% after 12 months. Seven 
studies (21%) used PRO as a primary endpoint, and the percentage of patients 
who answered the questionnaire answered was higher (mean 91%) than when 
PRO was a secondary endpoint (mean 79%). ConClusions: Careful consideration 
should be given to number of questionnaires used per study as quality decreases 
as number of evaluations increases.
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objeCtives: To confirm the factor structure of the Menopause-Specific Quality of 
Life (MENQOL) questionnaire for a vulvar/vaginal atrophy (VVA) population by apply-
ing confirmatory factor analysis (CFA), and to determine whether improvements in 
health-related quality of life (HRQL) observed in a VVA population with bazedox-
ifene/conjugated estrogens (BZA/CE) relative to placebo can be deemed clinically 
relevant. Methods: In a randomized control trial, postmenopausal women with 
≥ 1 bothersome moderate-to-severe VVA symptom received BZA 20 mg/CE 0.45 
or 0.625 mg, BZA 20mg or placebo for 12 weeks. HRQL and treatment satisfaction 
were evaluated using the MENQOL questionnaire and the Menopause Symptoms-
Treatment Satisfaction Questionnaire (MS-TSQ), respectively. The structure of the 
MENQOL questionnaire was evaluated using a CFA. Clinically important differences 
(CID) for the MENQOL were determined using a regression model to estimate dif-
ferences in domain and total scores corresponding to one category difference in 
MS-TSQ items, which were used as anchors. Results: The postulated CFA model fit 
the MENQOL data (Bentler’s Comparative Fit Index > 0.9). Treatment with BZA 20 mg/
CE 0.45 and 0.625 mg compared with placebo was associated with statistically sig-
nificant improvements in MENQOL vasomotor and sexual functioning domains, and 
total score (p < 0.001). BZA 20 mg/CE 0.625 mg was also associated with significant 
improvements in physical functioning (p= 0.019). Change from baseline in MENQOL 
vasomotor functioning for BZA 20 mg/CE 0.625 mg over placebo was greater than the 
estimated CID, with BZA 20 mg/CE 0.45 mg approaching CID. Changes in total score 
for BZA 20 mg/CE 0.625 mg compared with placebo also approacöhed CID. Changes 
in MENQOL sexual functioning from baseline over placebo, while statistically signifi-
cant and quite large, were less than the CID estimate. ConClusions: CFA modeling 
provides strong support for the existing factor structure of the MENQOL question-
naire. Improvements in HRQL seen with BZA/CE approached or exceeded CIDs for 
VMS functioning and total score.
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objeCtives: Follow up of pelvic floor muscle function after pelvic floor muscle 
training and using cube pessary, paying special attention to the changes in 
the strength of pelvic floor muscle and in the ability to relax. Methods: To 
determine the degree of the changes in the strength of pelvic floor muscle 
and in the ability to relax, 35 patients had been contacted before provided 
with cube pessaries and pelvic floor muscle training. Thirty out of 35 subjects 
supported our study. Five subjects were excluded due to vaginitis, so finally 30 
survey data were processed. Pelvic floor muscle function measurements were 
performed at the beginning when cube pessaries were given to the subjects 
and later after a 3-week period of usage. Patients were selected with the help of 
the non random sample method. Demographic data and gynecological history 
selection were based on our own general survey questionnaire, while FemiScan 
surface EMG was used to measure pelvic floor muscle strength and the ability to 
relax. Statistical analysis involved t-test or Mann-Whitney U-test, significance 
level was defined at p< 0.05. Results: Although pelvic floor muscle strength 
showed positive changes, statistically significant changes were not detected in 
the surveyed group. In the analysis of survey data of the ability to relax pelvic 
floor muscle statistically significant difference (p= 0,001) could be detected in 
the average results either at the beginning when cube pessaries were given to 
the subjects or after a 3-week period of usage. ConClusions: Cube pessary 
usage and pelvic floor muscle training may have a positive effect on pelvic 
floor muscle function.
factors were orthogonally combined to construct 16 patient profiles. All assumed 
medical care had the same ICER (cost per QALY). Respondents were randomly 
assigned to two of the 16 profiles and asked which one of the patients should 
preferentially receive treatment from a societal point of view, given a limited 
medical resource. Respondents were stratified by age and sex. Results: A total 
of 1091 responses were collected from 50 sites across Japan. The most preferred 
factor was “younger patient (a)”, followed by “treatment (b)” and “severe health 
state (c)”, which had the same degree of preference. No statistical significance 
was found for “no past experience of care (d)”. Public preference for medical care 
for elderly patients increased with increasing age. University-graduated people 
tended to prioritize care for patients who are younger and in severer condi-
tions. ConClusions: Our survey revealed that public medical care preferences 
are influenced by factors such as age, even with the same cost per QALY. Based 
on an economic evaluation, age is an important factor for decision-making that 
reflects societal preferences.
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objeCtives: Older people are particularly vulnerable to adverse effects of pre-
scribed drugs. PIP can be defined as the use of medicines with an unfavourable 
risk benefit ratio. There has been little research on the relationship between PIP 
and humanistic outcomes, such as functional impairment. This study aims to 
measure the prevalence of PIP in an older Irish population and to investigate its 
association with IADL impairment. Methods: A retrospective cohort study of 
2,051 community-dwelling participants in The Irish Longitudinal Study on Ageing 
(TILDA) aged ≥ 65 years with linked medication dispensing history from a national 
pharmacy claims database was carried out. Exposure to PIP in the 12 months prior 
to assessing functional impairment was determined using the Screening Tool for 
Older Persons’ Prescriptions (STOPP), the Beers’ criteria (2012) and Assessing Care 
of Vulnerable Elders (ACOVE) indicators relating to inappropriate medications. 
Logistic regression was used to determine the association between exposure to 
PIP and presence of any IADL impairment, adjusting for age, gender, socioeco-
nomic status, number of repeat drug classes co-morbidity and medication adher-
ence. Results: The overall prevalence of PIP was 66.89% (n= 1,372). Of these 514 
(25.06%) had one instance of PIP, while 858 (41.83%) had two or more. Prevalence 
was highest using the STOPP criteria (57.29%), compared to prevalences of 37.64% 
(Beers’ criteria) and 23.5% (ACOVE indicators. Participants with ≥ 2 PIP indicators 
were significantly more likely to have an IADL impairment (adjusted OR= 1.91; 
95%CI= 1.15-3.18) compared to no PIP. Similar associations were found for the 
individual measures of PIP. Age, number of repeat drug classes and co-morbidity 
were also significantly associated with IADL impairment. ConClusions: PIP in 
the elderly is highly prevalent and exposure to PIP is independently associated 
with increased risk of having IADL impairment. This suggests the importance of 
considering appropriateness when prescribing medicines in order to minimise 
adverse outcomes.
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objeCtives: Patient Reported Outcome Measures (PROMs) monitor both symp-
tom progression and treatment effectiveness, and play an increasing role in eve-
ryday clinical practice. Electronic PROMs (ePROMs) enable real-time reporting back 
to the patient and medical team, comparison with similar patient cohorts and 
long-term cost-effective outcome measurement. Concerns have, however, been 
expressed about electronic PROMs collection in the elderly. The primary objective 
of this three-phase pilot study was to measure uptake using a web-based ePROMs 
platform following the introduction of reminder short messaging service (SMS) 
before and Tablet Computer during clinic. Methods: Eighty-seven consecutive new 
elective orthopaedic patients in a single surgeon’s practice were recruited. Group 
1 (n= 27) received only a reminder letter, Group 2 (n= 34) also received a reminder 
SMS message via mobile or home telephone and Group 3 (n= 26) also had access to 
a Tablet Computer in clinic. Results: Mean age in Group 1 was 55.1 (24-77) years, 
Group 2 was 60.5 (23-85) years and Group 3 was 54.2 (17-77) years (p> 0.05). Overall 
75% patients had Internet access and 33% of Group 1, 50% of Group 2 and 73% 
of Group 3 recorded an ePROMs score (p= 0.03). In Group 2 and 3 26% of patients 
did not remember receiving a SMS message that was delivered. ConClusions: 
Collecting and using PROMs data in everyday clinical practice is challenging. This 
small pilot study shows that adding a reminder SMS before and access to a Tablet 
Computer during clinic improves ePROMs collection onto a clinical outcomes web-
based system. Further process improvements, such as additional staff training and 
telephone call reminders, might further improve uptake and a more comprehensive 
study is planned.
PIH43
EIgHty-nInE loCal roCHE sPonsorEd frEnCH studIEs PErformEd In tHE 
Past 10 yEars wErE EvaluatEd to dEtErmInE How PatIEnt rEPortEd 
outComEs wErE usEd
Pau D., Triglia A., Gavini F.
Roche, Boulogne-Billancourt, France
objeCtives: Patient Reported Outcomes (PROs) are increasingly used in clini-
cal studies as well as requested by health authorities (EMA, FDA). This descrip-
